Pfizer CEO Jeff Kindler has finally thrown out the Exubera baby with the bong water, saying, “We made an important decision regarding Exubera, a product for which we initially had high expectations. Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians. We have therefore concluded that further investment in this product is unwarranted.”
Exubera is the first inhalable insulin diabetes drug to market but was later pulled from the market because of poor sales due to doctors concerns about its long-term safety.
A video at PharmaGossip sums it up: